Finasteride

The document discusses the use of finasteride as a chemopreventive agent for prostate cancer. The Prostate Cancer Prevention Trial showed that finasteride can reduce the risk of developing prostate cancer. However, there is a discussion on the higher incidence of high-grade cancer in the finasteride arm. The document also mentions other chemopreventive agents for prostate cancer. Prostate cancer is the most common non-cutaneous malignancy in males in the US, and chemotherapeutic prevention studies are an attractive option given the high incidence of the disease, hormonal influences, and long latency period.